Target Price | $55.33 |
Price | $43.49 |
Potential |
27.23%
register free of charge
|
Number of Estimates | 21 |
21 Analysts have issued a price target Guardant Health, Inc. 2026 .
The average Guardant Health, Inc. target price is $55.33.
This is
27.23%
register free of charge
$65.00
49.46%
register free of charge
$20.00
54.01%
register free of charge
|
|
A rating was issued by 25 analysts: 22 Analysts recommend Guardant Health, Inc. to buy, 2 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Guardant Health, Inc. stock has an average upside potential 2026 of
27.23%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 739.02 | 856.43 |
31.04% | 15.89% | |
EBITDA Margin | -54.29% | -26.63% |
41.08% | 50.95% | |
Net Margin | -59.73% | -41.73% |
36.53% | 30.13% |
22 Analysts have issued a sales forecast Guardant Health, Inc. 2025 . The average Guardant Health, Inc. sales estimate is
This results in the following potential growth metrics:
16 Analysts have issued an Guardant Health, Inc. EBITDA forecast 2025. The average Guardant Health, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
19 Guardant Health, Inc. Analysts have issued a net profit forecast 2025. The average Guardant Health, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -3.56 | -2.88 |
16.82% | 19.10% | |
P/E | negative | |
EV/Sales | 6.85 |
19 Analysts have issued a Guardant Health, Inc. forecast for earnings per share. The average Guardant Health, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Guardant Health, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Stephens & Co. |
Locked
➜
Locked
|
Locked | Mar 26 2025 |
Morgan Stanley |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
Scotiabank |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
Guggenheim |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
Canaccord Genuity |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Feb 21 2025 |
Analyst Rating | Date |
---|---|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Mar 26 2025 |
Locked
Morgan Stanley:
Locked
➜
Locked
|
Mar 06 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Feb 26 2025 |
Locked
Scotiabank:
Locked
➜
Locked
|
Feb 24 2025 |
Locked
Guggenheim:
Locked
➜
Locked
|
Feb 24 2025 |
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Feb 24 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Feb 21 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.